Nanalysis Scientific Corp. Closes a public offering and a simultaneous private placement without intermediary for gross proceeds of C $ 10,997,686


CALGARY, AB, 25 August 2021 / CNW / – Nanalysis Scientific Corp. Nanalysis Scientific Corp. (“The Company”), (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), announces the closing of the previously announced public offering (the “Placement”) of units (the “Units”) of the Company and the simultaneous private placement of Units without an intermediary (the “Private Placement”) for combined gross proceeds of CA $ 10,997,686.40.

Pursuant to the public placement, the Company issued 7,666,706 units, including 1,000,006 units issued pursuant to the exercise of the underwriters’ over-allotment option, at a price per unit of CA $ 1.20 for the total gross proceeds of CA $ 9,200,047.20. Each unit consists of one common share (each a “common share”) and one-half of the Company’s common share purchase warrant (each full common share purchase warrant, a “warrant” ). Each warrant may be exercised to acquire one common share of the Company at an exercise price of CA $ 1.70 by mandate up to August 25, 2023, subject to adjustment in certain cases.

Echelon Wealth Partners Inc., as sole underwriter and bookrunner, and Leede Jones Gable Inc. acted as underwriters for the public offering.

A total of 1,498,032 units were issued under the private placement at a price of CA $ 1.20 per Share for the gross proceeds accruing to the Company from CA $ 1,797,639.20. Each unit issued under the private placement consists of one common share and one half warrant. Each warrant may be exercised to acquire one common share of the Company at an exercise price of CA $ 1.70 by mandate up to August 25, 2023, subject to adjustment in certain cases.

The Company intends to use the net proceeds of the Public Offer for sales, marketing, research and development, acquisitions, general administration and working capital purposes. The net proceeds of the private placement will be used for general corporate and other working capital purposes, as well as for other potential acquisitions.

The common shares and warrants issued in connection with the private placement are subject to a hold period of four months plus one day from the closing date of the private placement. Final acceptance by the TSX Venture Exchange (the “TSXV”) of the public offer and private placement is subject to the completion of customary post-closing deposits.

On Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with the symbol ‘NSCI’, Over the Counter (OTC) in United States under the ticker symbol “NSCIF” and on the Frankfurt Stock Exchange (FRA) under the symbol “1N1”.

Nanalysis is an international company focused on capitalizing on its proprietary magnetic resonance (MR) technologies that enter NMR spectrometers and magnetic resonance imaging (MRI). Nanalysis operates from two subsidiaries, Nanalysis Corp. and RS2D SAS (RS2D).

Nanalysis Corp. is an industry leader in the development and manufacture of compact RM spectrometers for the laboratory and industrial markets. Its advanced 60 and 100 MHz spectrometers do not require liquid helium or other cryogens. These devices are used by chemical professionals spanning a wide variety of industries including oil and gas, chemicals, mining, pharmaceuticals and biotechnology.

Through its European subsidiary RS2D, the Company’s electronic cards and software are used in conventional NMR and MRI equipment and are integrated into new generation MRI systems as well as MRI machines. miniaturized.

Notice regarding forward-looking statements and legal notices

This press release contains certain “forward-looking statements” within the meaning of such statements under applicable securities laws regarding the use of the net proceeds of the public placement and the private placement, the final acceptance of the public placement and the private placement. by TSXV and other matters incidental or incidental to the above.

All statements included in this document, other than statements of historical fact, may be forward-looking information and such information involves various risks and uncertainties. Forward-looking information is often, but not always, identified by the use of words such as “Anticipates”, “plans”, “continues”, “expects”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “can”, “can” , “Possible”, “propose” “,” positioned “and other similar words, or statements that certain events or conditions” may “or” will “occur. These statements are only predictions. Various assumptions have been used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to various risks and uncertainties and other factors that could cause actual events or results to differ. substantially from those projected in the forward forecast. staring statements. The Company has no obligation and expressly disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. .

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCENanalysis Scientific Corp.

For more information: Luke Caplette, CFO, Nanalysis Scientific Corp., T: +1.403.831.6968, E: [email protected]

Related links

Leave A Reply

Your email address will not be published.